I n October 2004, a Web site of special interest to health care providers will be launched on the Internet. New Web sites related to health care appear every day, so why is this news? The site (www.clinicalstudyresults.org), operated by the Pharmaceutical Research and Manufacturers of America (PhRMA), is notable because it will provide practitioners with access -for the first time -to published and unpublished clinical trial results.
Historically, most published medical research has included only trials with positive or equivocal results. Trials with negative results generally have not been published in the medical literature. This means that practitioners have not been getting the "whole story" about the safety and efficacy of drugs, medical devices, and procedures from the medical literature. One existing Web site (http:// clinicaltrials.gov) lists all registered clinical trials, but it does not describe their results.
Anyone that has ever conducted or read a systematic review or a meta-analysis can tell you that information from trials with negative results is sparse and difficult to identify. The absence of negative results has been an issue for years, but it came to a critical point this year because of a lawsuit against a pharmaceutical manufacturer. The plaintiff charged that the company failed to release negative trial results about one of their medications. In response to this lawsuit, GlaxoSmithKline, Merck, and Eli Lilly announced that they would begin to post results from clinical trials -including negative results -on the Internet.
The introduction of the PhRMA Web site is an important step toward easy access to all clinical trial results. As planned, it will operate as a free, central, Webbased database of clinical trial results. It will contain information from clinical trials (mainly phase III and IV) related to marketed drugs that are classified as "hypothesis-testing." Summaries from trials completed since October 1, 2002 will be provided by the PhRMA-member companies. The member companies will be encouraged to post unpublished trials within 1 year of completion.
The database will be presented in a standardized format. It will include the sponsoring company's name, the proprietary and generic names of the drug, a link or reference to the FDA-approved labeling, the studied indication or disease, a bibliography of published trials with a link (when available) to printed articles, and a standardized summary of unpublished trials. The information will also include the study center, the trial design, the number of patients studied, the dose and mode of administration, and a summary of the conclusions and outcomes.
The www.clinicalstudyresults. org site will initially be operated by PhRMA, but the organization hopes to transfer administration of the database to an independent third party in the future.
Participation in the site's database is voluntary by the member pharmaceutical companies. This voluntary aspect has been criticized by some researchers and practitioners.
However, the resource is a definite step in the right direction, much like the inclusion of unpublished data in the AMCP's Format Dossier for Formulary Submission. When the new site becomes available in October, practitioners will have access to both positive and negative clinical trial results. ■
